Patient-reported functional outcome measures and treatment choice for prostate cancer.
Tenaw Tiruye, Michael O'Callaghan, Kim Moretti...
https://pubmed.ncbi.nlm.nih.gov/36335325/Actively Recruiting
Led by Melbourne Health · Updated on 2024-08-26
10000
Participants Needed
8
Research Sites
N/A
Total Duration
Researchers are studying prostate cancer treatment outcomes in men undergoing robotic-assisted radical prostatectomy RARP in Australia. This observational study aims to gather long-term data on surgical, oncological, and patient-reported outcomes, addressing gaps in current knowledge about the benefits and costs of robotic surgery compared to other methods. The study also explores surgeon learning curves and aims to improve care standards across both metropolitan and rural hospitals. Participants will be men aged 18 to 90 years with localized prostate cancer who receive medical care at participating hospitals. The study collects information through a national database that records surgical details, oncological results, and patient-reported quality of life measures at multiple time points before surgery, then at 4 weeks, 6 months, 12 months, 24 months, and 36 months post-surgery. This approach allows researchers to analyze trends and differences in outcomes over time. During the study, participants provide consent for their health information to be collected and monitored. Patient questionnaires and clinical data are gathered at specified intervals to assess the impact of robotic surgery on quality of life and cancer control. The primary goal is to develop evidence-based guidelines to help personalize prostate cancer management and support decision-making for patients and healthcare providers nationwide.
CONDITIONS
National Robotics-Assisted Radical Prostatectomy Database
N
Nathan Lawrentschuk, MBBS,PhD, FRACS
F
Farleigh Reeves, MBBS, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Melbourne Health
Lead Sponsor
Peter MacCallum Cancer Centre, Australia
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Hospital stay of approximately 1 to 2 days
Participants undergo robotic-assisted radical prostatectomy and receive immediate post-operative care.
1 surgical visit and hospital stay
Duration - Up to 36 months post-surgery
Participants are monitored with surgical, oncological, and patient-reported quality of life assessments after surgery.
Visits at baseline, 4 weeks, 6 months, 12 months, 24 months, and 36 months post-surgery
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Tenaw Tiruye, Michael O'Callaghan, Kim Moretti...
https://pubmed.ncbi.nlm.nih.gov/36335325/Sachin Perera, Nadil Fernando, Jonathan O'Brien...
https://pubmed.ncbi.nlm.nih.gov/36910896/Jón Örn Fridriksson, Yasin Folkvaljon, Karl-Johan Lundström...
https://pubmed.ncbi.nlm.nih.gov/28591934/Thenappan Chandrasekar, Derya Tilki
https://pubmed.ncbi.nlm.nih.gov/28607497/Melbourne Health
Lead Sponsor
Peter MacCallum Cancer Centre, Australia
Collaborating Sponsor